Index RUT P/E - EPS (ttm) -3.70 Insider Own 7.45% Shs Outstand 77.93M Perf Week 13.20%
Market Cap 3.72B Forward P/E - EPS next Y -3.54 Insider Trans -7.14% Shs Float 72.12M Perf Month 2.21%
Income -214.53M PEG - EPS next Q -0.81 Inst Own 89.80% Short Float 7.24% Perf Quarter 28.59%
Sales 0.00M P/S - EPS this Y 13.21% Inst Trans 1.42% Short Ratio 6.44 Perf Half Y 61.35%
Book/sh 7.91 P/B 6.03 EPS next Y -10.42% ROA -43.45% Short Interest 5.22M Perf Year 121.05%
Cash/sh 7.17 P/C 6.65 EPS next 5Y - ROE -50.16% 52W Range 15.76 - 49.58 Perf YTD 34.01%
Dividend Est. - P/FCF - EPS past 5Y -10.59% ROI -36.57% 52W High -3.83% Beta 0.65
Dividend TTM - Quick Ratio 13.07 Sales past 5Y 64.83% Gross Margin -105.50% 52W Low 202.54% ATR (14) 2.18
Dividend Ex-Date - Current Ratio 13.07 EPS Y/Y TTM -17.50% Oper. Margin 0.00% RSI (14) 62.57 Volatility 4.97% 4.93%
Employees 290 Debt/Eq 0.10 Sales Y/Y TTM -100.00% Profit Margin - Recom 1.21 Target Price 57.14
Option/Short Yes / Yes LT Debt/Eq 0.09 EPS Q/Q -7.10% Payout - Rel Volume 0.78 Prev Close 46.78
Sales Surprise -100.00% EPS Surprise -4.35% Sales Q/Q -100.00% Earnings May 09 AMC Avg Volume 811.42K Price 47.68
SMA20 6.95% SMA50 9.80% SMA200 47.12% Trades
Volume 316,764 Change 1.92%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-06-24 Initiated Citigroup
Buy
$68
Jan-16-24 Initiated Morgan Stanley
Overweight
$50
Dec-21-23 Initiated Jefferies
Hold
$35
Nov-20-23 Resumed JP Morgan
Overweight
$35
Oct-24-23 Resumed Cantor Fitzgerald
Overweight
$52 → $50
Aug-31-23 Initiated Oppenheimer
Outperform
$40
Apr-24-23 Initiated Piper Sandler
Overweight
$56
Mar-30-23 Initiated Robert W. Baird
Outperform
$48
Nov-30-21 Initiated JMP Securities
Mkt Outperform
$43
Nov-23-21 Initiated Evercore ISI
Outperform
$68
Jun-18-21 Upgrade JP Morgan
Neutral → Overweight
$28
Dec-23-19 Initiated ROTH Capital
Buy
$37
Feb-14-19 Initiated H.C. Wainwright
Buy
$35
Aug-13-18 Initiated Piper Jaffray
Overweight
$40
Aug-13-18 Initiated Leerink Partners
Outperform
$43
Aug-13-18 Initiated JP Morgan
Neutral
$29
Show Previous Ratings
May-02-24 04:05PM
Apr-11-24 04:05PM
Mar-28-24 08:10AM
Mar-26-24 07:01PM
Mar-22-24 07:02PM
07:02PM
Loading…
07:02PM
Mar-21-24 02:32AM
Mar-20-24 11:46AM
05:14AM
Mar-19-24 04:48PM
04:03PM
(Investor's Business Daily)
08:08AM
(Investor's Business Daily)
06:16AM
06:08AM
06:00AM
04:05PM
Loading…
Mar-12-24 04:05PM
Mar-11-24 04:05PM
Mar-01-24 08:57AM
Feb-28-24 04:36PM
04:05PM
08:00AM
Feb-15-24 03:14AM
Feb-14-24 04:05PM
Feb-12-24 04:05PM
Jan-26-24 11:01PM
Jan-13-24 05:03AM
Jan-10-24 04:33PM
Jan-05-24 03:03AM
Jan-03-24 08:00AM
Dec-29-23 07:02AM
05:01AM
Loading…
Dec-23-23 05:01AM
Dec-18-23 04:05PM
Dec-11-23 04:05PM
Dec-03-23 05:25AM
Nov-20-23 04:05PM
Nov-17-23 08:39AM
Nov-10-23 05:00PM
Nov-09-23 05:45AM
Nov-08-23 09:55AM
08:50AM
Nov-07-23 04:05PM
Nov-04-23 05:03AM
Oct-23-23 09:55AM
08:50AM
Oct-20-23 01:02AM
Oct-11-23 09:00AM
Oct-10-23 05:00PM
Oct-03-23 07:00AM
Sep-28-23 11:18AM
Sep-20-23 08:00AM
Sep-15-23 08:37AM
Sep-12-23 10:26PM
Sep-11-23 04:04PM
(Investor's Business Daily) +63.31%
04:01PM
12:57PM
06:00AM
05:43AM
Sep-10-23 10:00AM
Sep-05-23 08:55PM
Aug-13-23 09:02AM
Aug-10-23 05:34PM
Aug-08-23 07:00AM
Jul-31-23 08:01AM
Jul-10-23 04:18PM
Jun-21-23 07:59AM
Jun-12-23 07:30AM
Jun-09-23 07:30AM
May-10-23 04:21PM
May-06-23 08:07AM
May-04-23 07:35PM
04:05PM
10:00AM
Apr-16-23 09:34AM
Apr-10-23 04:31PM
Mar-28-23 03:57PM
Mar-10-23 04:37PM
Mar-06-23 07:05AM
Feb-28-23 05:25PM
04:05PM
Feb-10-23 05:21PM
08:01AM
Jan-10-23 04:48PM
Jan-09-23 08:01AM
Dec-12-22 04:01PM
Nov-28-22 08:00AM
Nov-22-22 08:00AM
Nov-14-22 09:15AM
08:00AM
Nov-10-22 04:30PM
Nov-06-22 07:26AM
Oct-13-22 08:00AM
Oct-10-22 04:57PM
Oct-06-22 08:00AM
Oct-03-22 08:00AM
Sep-26-22 10:29AM
Sep-12-22 08:00AM
Sep-08-22 08:00AM
Sep-06-22 08:00AM
Sep-02-22 08:00AM
Aug-12-22 09:15AM
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Pizzuti Dana Chief Med and Dev Officer Apr 15 '24 Option Exercise 16.89 14,375 242,794 42,161 Apr 17 04:36 PM Struthers Richard Scott President & CEO Apr 15 '24 Option Exercise 1.91 20,000 38,200 257,835 Apr 17 04:30 PM Pizzuti Dana Chief Med and Dev Officer Apr 15 '24 Sale 44.47 14,375 639,256 27,786 Apr 17 04:36 PM Struthers Richard Scott President & CEO Apr 04 '24 Option Exercise 9.28 40,951 380,025 278,786 Apr 08 05:09 PM Struthers Richard Scott President & CEO Apr 04 '24 Sale 49.17 40,951 2,013,561 237,835 Apr 08 05:09 PM Okey Stephanie Director Mar 28 '24 Option Exercise 18.29 17,500 320,075 23,500 Apr 02 04:35 PM Okey Stephanie Director Mar 28 '24 Sale 46.38 17,500 811,650 6,000 Apr 02 04:35 PM Knight Jeff E. Chief Operating Officer Mar 22 '24 Option Exercise 23.98 30,000 719,400 84,939 Mar 26 04:30 PM Knight Jeff E. Chief Operating Officer Mar 22 '24 Sale 44.31 32,359 1,433,675 52,580 Mar 26 04:30 PM Fust Matthew K Director Mar 20 '24 Option Exercise 20.92 60,000 1,254,975 36,036 Mar 22 04:31 PM Pizzuti Dana Chief Med and Dev Officer Mar 20 '24 Option Exercise 16.89 14,375 242,794 38,500 Mar 22 04:52 PM Fust Matthew K Director Mar 20 '24 Sale 44.14 60,000 2,648,150 18,536 Mar 22 04:31 PM Pizzuti Dana Chief Med and Dev Officer Mar 20 '24 Sale 44.06 15,089 664,763 27,786 Mar 22 04:52 PM Wilson Marc CFO Mar 19 '24 Sale 42.91 6,942 297,881 110,630 Mar 20 06:32 PM Betz Stephen F. Chief Scientific Officer Jan 25 '24 Sale 37.26 3,000 111,780 73,298 Jan 26 05:50 PM Betz Stephen F. Chief Scientific Officer Jan 10 '24 Sale 37.65 3,000 112,950 76,298 Jan 12 04:12 PM Pizzuti Dana Chief Med and Dev Officer Jan 03 '24 Option Exercise 16.89 14,375 242,794 20,286 Jan 04 04:45 PM Pizzuti Dana Chief Med and Dev Officer Jan 03 '24 Sale 35.00 14,375 503,125 5,911 Jan 04 04:45 PM Wilson Marc CFO Jan 02 '24 Option Exercise 9.28 10,000 92,800 106,055 Jan 04 04:43 PM Wilson Marc CFO Jan 02 '24 Sale 35.47 10,000 354,700 96,055 Jan 04 04:43 PM Betz Stephen F. Chief Scientific Officer Dec 26 '23 Sale 35.89 3,000 107,670 79,298 Dec 27 05:20 PM Pizzuti Dana Chief Med and Dev Officer Dec 21 '23 Option Exercise 16.89 9,583 161,857 15,494 Dec 22 06:45 PM Pizzuti Dana Chief Med and Dev Officer Dec 21 '23 Sale 34.57 9,583 331,284 5,911 Dec 22 06:45 PM Betz Stephen F. Chief Scientific Officer Dec 11 '23 Sale 32.87 3,000 98,610 82,298 Dec 13 04:44 PM Betz Stephen F. Chief Scientific Officer Nov 27 '23 Sale 31.84 3,000 95,520 85,298 Nov 29 04:31 PM Struthers Richard Scott President & CEO Nov 09 '23 Option Exercise 1.91 50,000 95,500 185,522 Nov 13 04:33 PM Struthers Richard Scott President & CEO Nov 03 '23 Option Exercise 9.28 199,082 1,847,481 334,604 Nov 06 06:02 PM Struthers Richard Scott President & CEO Nov 03 '23 Sale 30.56 199,082 6,083,946 135,522 Nov 06 06:02 PM Struthers Richard Scott President & CEO Nov 02 '23 Option Exercise 9.28 918 8,519 136,440 Nov 06 06:02 PM Struthers Richard Scott President & CEO Nov 02 '23 Sale 29.95 918 27,494 135,522 Nov 06 06:02 PM Wilson Marc CFO Nov 01 '23 Option Exercise 9.28 10,000 92,800 105,601 Nov 03 07:38 PM Wilson Marc CFO Nov 01 '23 Sale 28.75 10,000 287,500 95,601 Nov 03 07:38 PM Krasner Alan Seth Chief Medical Officer Oct 17 '23 Option Exercise 12.01 7,000 84,070 50,210 Oct 19 05:01 PM Krasner Alan Seth Chief Medical Officer Oct 17 '23 Sale 30.00 7,000 210,000 43,210 Oct 19 05:01 PM Struthers Richard Scott President & CEO Aug 14 '23 Option Exercise 1.91 10,000 19,100 135,522 Aug 16 04:30 PM Struthers Richard Scott President & CEO Jul 13 '23 Sale 20.35 14,157 288,095 630,805 Jul 13 04:56 PM Struthers Richard Scott President & CEO Jul 12 '23 Sale 20.17 11,459 231,128 644,962 Jul 13 04:56 PM Struthers Richard Scott President & CEO Jul 11 '23 Sale 20.14 24,384 491,094 656,421 Jul 13 04:56 PM Wilson Marc CFO Jun 20 '23 Option Exercise 9.28 20,000 185,600 115,158 Jun 21 05:32 PM Wilson Marc CFO Jun 20 '23 Sale 19.97 30,922 617,403 95,158 Jun 21 05:32 PM Struthers Richard Scott President & CEO Jun 16 '23 Sale 20.81 50,000 1,040,500 680,805 Jun 21 05:27 PM Vivaldi Coelho Rogerio Director Jun 08 '23 Buy 22.06 5,000 110,300 5,000 Jun 09 08:00 AM
Index - P/E - EPS (ttm) -8.03 Insider Own 6.45% Shs Outstand 82.31M Perf Week 0.90%
Market Cap 3.68B Forward P/E - EPS next Y -5.08 Insider Trans -1.83% Shs Float 77.02M Perf Month -5.18%
Income -613.35M PEG - EPS next Q -1.69 Inst Own 104.15% Short Float 5.69% Perf Quarter 3.77%
Sales 442.59M P/S 8.30 EPS this Y 20.85% Inst Trans -3.16% Short Ratio 6.11 Perf Half Y 23.86%
Book/sh 3.35 P/B 13.34 EPS next Y 22.28% ROA -45.59% Short Interest 4.38M Perf Year 3.02%
Cash/sh 6.91 P/C 6.46 EPS next 5Y 8.90% ROE -340.05% 52W Range 31.52 - 54.98 Perf YTD -6.65%
Dividend Est. - P/FCF - EPS past 5Y -15.75% ROI -52.50% 52W High -18.81% Beta 0.62
Dividend TTM - Quick Ratio 2.49 Sales past 5Y 63.06% Gross Margin 93.44% 52W Low 41.62% ATR (14) 2.04
Dividend Ex-Date - Current Ratio 2.61 EPS Y/Y TTM 17.65% Oper. Margin -131.08% RSI (14) 47.84 Volatility 3.56% 4.85%
Employees 1276 Debt/Eq 6.66 Sales Y/Y TTM 15.29% Profit Margin -138.58% Recom 1.29 Target Price 89.24
Option/Short Yes / Yes LT Debt/Eq 6.37 EPS Q/Q 13.10% Payout - Rel Volume 1.61 Prev Close 43.20
Sales Surprise -6.20% EPS Surprise -16.19% Sales Q/Q 8.30% Earnings May 02 AMC Avg Volume 717.57K Price 44.64
SMA20 -1.85% SMA50 -5.88% SMA200 6.02% Trades
Volume 576,700 Change 3.33%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-22-24 Initiated RBC Capital Mkts
Outperform
$77
Dec-08-23 Initiated Wells Fargo
Overweight
$72
Jun-14-23 Resumed Credit Suisse
Outperform
$96
Jun-06-23 Upgrade Evercore ISI
In-line → Outperform
$60 → $80
Apr-26-23 Initiated Cantor Fitzgerald
Overweight
$114
Jan-18-23 Resumed Canaccord Genuity
Buy
$90
Dec-30-22 Resumed H.C. Wainwright
Buy
$82
Nov-03-22 Upgrade Robert W. Baird
Neutral → Outperform
$50
Oct-13-22 Upgrade Guggenheim
Neutral → Buy
$50
Aug-01-22 Downgrade Evercore ISI
Outperform → In-line
$95 → $60
Mar-16-22 Upgrade Credit Suisse
Neutral → Outperform
$99 → $105
Feb-11-22 Upgrade JP Morgan
Neutral → Overweight
$132
Sep-30-21 Initiated H.C. Wainwright
Buy
$106
Aug-19-21 Initiated UBS
Sell
$73
Jul-15-21 Initiated Guggenheim
Neutral
Jun-29-21 Upgrade BofA Securities
Neutral → Buy
$162
Jun-04-21 Resumed Robert W. Baird
Neutral
$109
May-06-21 Upgrade Evercore ISI
In-line → Outperform
$144
May-06-21 Upgrade Citigroup
Neutral → Buy
$160 → $151
Apr-26-21 Resumed Credit Suisse
Neutral
$99
Show Previous Ratings
May-02-24 08:58PM
08:00PM
05:49PM
05:10PM
04:08PM
(Associated Press Finance)
04:00PM
Loading…
04:00PM
Apr-30-24 04:00PM
08:00AM
Apr-25-24 04:30PM
Apr-19-24 04:30PM
Apr-16-24 11:33AM
Apr-15-24 07:30AM
07:00AM
Apr-12-24 04:22PM
08:00AM
04:00PM
Loading…
Mar-22-24 04:00PM
Mar-20-24 08:11AM
Mar-12-24 05:00PM
Mar-11-24 03:00PM
Mar-08-24 09:38AM
Feb-27-24 04:30PM
Feb-23-24 04:05PM
Feb-16-24 10:43AM
10:35AM
(Thomson Reuters StreetEvents)
07:53AM
Feb-15-24 04:15PM
(Associated Press Finance)
04:01PM
Feb-13-24 01:36PM
Feb-08-24 04:00PM
Feb-06-24 08:00AM
04:05PM
Loading…
Feb-05-24 04:05PM
Jan-25-24 04:05PM
Jan-19-24 04:00PM
Jan-18-24 02:41PM
(Investor's Business Daily)
Jan-09-24 06:20PM
Jan-08-24 12:18PM
07:00AM
Jan-07-24 11:00AM
Jan-04-24 08:12AM
08:00AM
Jan-03-24 08:00AM
Jan-02-24 04:05PM
Dec-27-23 06:41PM
Dec-21-23 05:21PM
(The Wall Street Journal)
04:30PM
Dec-18-23 09:29AM
08:00AM
Dec-15-23 10:18AM
Nov-20-23 04:30PM
Nov-17-23 04:30PM
Nov-07-23 05:00PM
Nov-04-23 01:12PM
12:16PM
Nov-03-23 11:43AM
Nov-02-23 06:26PM
04:36PM
(Associated Press Finance)
04:05PM
Oct-26-23 04:05PM
Oct-25-23 06:17AM
Oct-23-23 04:01PM
04:01PM
Oct-20-23 04:00PM
Oct-18-23 09:16PM
Oct-17-23 04:02PM
Oct-16-23 08:00AM
Oct-14-23 04:30PM
Oct-12-23 05:00PM
Oct-09-23 08:00AM
Oct-05-23 08:00AM
Sep-25-23 05:13PM
Sep-20-23 05:00PM
Sep-07-23 12:36PM
Aug-31-23 09:00AM
Aug-18-23 05:00PM
Aug-12-23 11:05AM
Aug-11-23 11:14AM
(American City Business Journals)
Aug-10-23 06:27PM
Aug-08-23 07:11AM
06:20AM
Aug-04-23 08:34AM
(Thomson Reuters StreetEvents) -8.79%
08:12AM
Aug-03-23 04:09PM
04:00PM
Jul-31-23 08:00AM
Jul-27-23 05:00PM
05:05AM
(American City Business Journals)
Jul-18-23 05:00PM
Jul-13-23 03:00PM
Jul-12-23 08:00AM
Jul-07-23 07:46AM
Jul-06-23 08:00AM
Jun-28-23 11:06AM
Jun-21-23 08:00AM
Jun-20-23 05:00PM
Jun-09-23 10:55AM
Jun-07-23 05:00PM
03:21AM
Jun-05-23 04:00PM
May-24-23 06:39AM
May-19-23 08:30AM
Ultragenyx Pharmaceutical, Inc. engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Crombez Eric EVP and Chief Medical Officer Apr 18 '24 Sale 44.10 142 6,262 48,785 Apr 19 04:35 PM Kassberg Thomas Richard CBO & EVP Mar 11 '24 Sale 49.93 11,509 574,644 252,823 Mar 12 01:41 PM Fust Matthew K Director Mar 07 '24 Sale 50.88 12,195 620,443 14,860 Mar 11 12:54 PM Harris Erik EVP & Chief Commercial Officer Mar 01 '24 Sale 53.76 4,768 256,328 67,163 Mar 05 08:08 PM Pinion John Richard See Remarks Mar 01 '24 Sale 53.76 4,173 224,340 89,268 Mar 05 08:15 PM Parschauer Karah Herdman EVP and Chief Legal Officer Mar 01 '24 Sale 53.76 3,756 201,923 67,340 Mar 05 08:22 PM Crombez Eric EVP and Chief Medical Officer Mar 01 '24 Sale 53.76 1,238 66,555 48,927 Mar 05 08:10 PM Kassberg Thomas Richard CBO & EVP Mar 01 '24 Sale 53.76 1,011 54,351 264,332 Mar 05 08:19 PM Huizenga Theodore Alan SVP, Chief Accounting Officer Mar 01 '24 Sale 53.76 341 18,332 41,380 Mar 05 08:13 PM KAKKIS EMIL D President & CEO Feb 07 '24 Sale 45.00 30,000 1,350,000 539,770 Feb 08 03:49 PM Huizenga Theodore Alan SVP, Chief Accounting Officer Jan 02 '24 Option Exercise 21.00 3,000 63,000 27,892 Jan 02 04:06 PM KAKKIS EMIL D President & CEO Dec 29 '23 Sale 47.87 30,000 1,436,100 569,770 Jan 02 04:07 PM Kassberg Thomas Richard CBO & EVP Oct 23 '23 Option Exercise 6.86 39,878 273,563 286,738 Oct 24 05:22 PM Kassberg Thomas Richard CBO & EVP Oct 23 '23 Sale 32.78 39,878 1,307,201 246,860 Oct 24 05:22 PM KAKKIS EMIL D President & CEO Oct 19 '23 Option Exercise 6.86 47,853 328,272 647,029 Oct 23 05:14 PM KAKKIS EMIL D President & CEO Oct 19 '23 Sale 33.52 47,853 1,604,033 599,743 Oct 23 05:14 PM Huizenga Theodore Alan SVP, Chief Accounting Officer Sep 07 '23 Option Exercise 21.00 2,000 42,000 25,777 Sep 11 01:52 PM Huizenga Theodore Alan SVP, Chief Accounting Officer Sep 07 '23 Sale 40.80 2,163 88,249 23,614 Sep 11 01:52 PM Harris Erik EVP & Chief Commercial Officer Sep 05 '23 Sale 37.96 6,000 227,760 51,281 Sep 06 05:51 PM Huizenga Theodore Alan SVP, Chief Accounting Officer Sep 01 '23 Sale 37.15 970 36,032 23,777 Sep 06 05:50 PM Sanders Corazon (Corsee) D. Director Jun 30 '23 Sale 46.76 585 27,355 8,985 Jun 30 02:34 PM Harris Erik EVP & Chief Commercial Officer Jun 19 '23 Sale 48.20 305 14,701 57,281 Jun 21 06:17 PM Sanders Corazon (Corsee) D. Director Jun 08 '23 Sale 51.65 1,485 76,700 9,570 Jun 09 02:31 PM Pinion John Richard See Remarks May 18 '23 Sale 50.00 2,012 100,600 74,744 May 19 01:54 PM Huizenga Theodore Alan SVP, Chief Accounting Officer May 09 '23 Option Exercise 21.00 3,000 63,000 30,747 May 10 08:09 PM Parschauer Karah Herdman EVP and Chief Legal Officer May 04 '23 Sale 45.00 4,378 197,010 51,982 May 05 02:16 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
